Transplant Biomedical receives an economical injection to develop an organ preservation device

Transplant Biomedical, one of the two spin-offs arising from IDIBAPS, will receive a maximum of 2.5 million euros to carry out the clinical phase of a medical device intended to improve the preservation and transport of kidneys and livers for transplantation. This economic injection is the result of an agreement with Caixa Capital Risc and Kereon Partners, the company founded, among others, by Carmen Peralta, coordinator of the group Strategies for the protection of hepatic injury induced by ischemia-reperfusion.

Transplant Biomedical develops products to improve the preservation of organs, tissues and cells, for instance during transport between the donor hospital and the recipient. Preclinical results indicate that TB-1, the scientific name of this device, will increase the number of organs suitable for transplantation as well as the survival rate of patients. In addition to the clinical trial, the investment will cover the technological development of the device and the obtaining of CE marking to start sales in Europe in 2018.

This is the first round of investment that closes in the field of health in Spain in 2017. Since 2014, Transplant Biomedical has accumulated 3.5 million euros obtained from venture capital, that is why it has become the entity of nondiagnostic medical devices that captured more private capital in Spain.

Caption: Sitting: Ignasi Heras and Carmen Peralta, Transplant Biomedical. Standing: Joaquín Sanz, Alex Casta, and Josep Gatell, of the investment companies.